If you review their pipeline and those of their partners, I think you'll find that they have many different cancers they're after. Pay special attention to the Bayer drug, it is in a registrational Phase 2 trial. This trial is scheduled to complete this year, the IMGN853 trial isn't expected to complete until 2020.
News 
Market Data 
Discover 
